Increased Risk of End-Stage Kidney Disease in Patients with Chronic Kidney Disease and Heart Failure with Reduced Ejection Fraction
- PMID: 38952127
- DOI: 10.1159/000540121
Increased Risk of End-Stage Kidney Disease in Patients with Chronic Kidney Disease and Heart Failure with Reduced Ejection Fraction
Abstract
Introduction: The prevalence of heart failure (HF) is more common in people with advanced non-dialysis chronic kidney disease (ND-CKD) compared to the general population. It is well known that HF with reduced ejection fraction (HFrEF) is associated with a higher risk of mortality in people with ND-CKD. However, the impact of HFrEF on progression into end-stage kidney disease (ESKD) is not well studied. Our study aimed to examine the independent association of HFrEF on progression to ESKD after correcting for confounding factors using two methods of propensity scoring.
Methods: This study used data from the Salford Kidney Study, a longitudinal study which has recruited more than 3,000 patients with ND-CKD since 2002. Patients without a history of HF during the recruitment questionnaire were included in the control group. Patients with a reported history of HF and echo showing left ventricular ejection fraction <40% at enrolment were included in the HFrEF group. Two propensity score methods were used to attenuate the effects of confounding factors between the two groups - propensity score matching (PSM) and inverse probability weighting (IPW). Univariate and multivariate Cox-regression analyses were performed.
Results: A total of 2,383 patients were included in the analysis. Patients with HFrEF had significantly higher median age and a higher percentage of male gender compared to patients with no HF (72.5 vs. 66.6 years and 71.8 vs. 61.1%, respectively). Univariate and 5 models of multivariate Cox-regression analysis showed that HFrEF in people with CKD was a strong predictor for a higher incidence of ESKD (model 5: hazard ratio 1.38; 95% confidence interval = 1.01-1.90; p = 0.044). The association between HFrEF and the risk of ESKD remained significant after using the PSM and the IPW methods.
Conclusion: Patients with concomitant advanced ND-CKD and prevalent HFrEF were found to have a higher risk of ESKD when compared to patients with no HF. This risk persists despite the adjustment of confounding factors using PSM and IPW.
Keywords: Cardiorenal syndrome; Chronic kidney disease; End-stage kidney disease; Heart failure; Heart failure with reduced ejection fraction.
© 2024 The Author(s). Published by S. Karger AG, Basel.
Similar articles
-
Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease.Circ Heart Fail. 2024 May;17(5):e011173. doi: 10.1161/CIRCHEARTFAILURE.123.011173. Epub 2024 May 14. Circ Heart Fail. 2024. PMID: 38742428 Free PMC article.
-
Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.Eur J Heart Fail. 2017 Dec;19(12):1606-1614. doi: 10.1002/ejhf.821. Epub 2017 Mar 29. Eur J Heart Fail. 2017. PMID: 28371075
-
The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction.Eur J Heart Fail. 2017 May;19(5):615-623. doi: 10.1002/ejhf.778. Epub 2017 Feb 20. Eur J Heart Fail. 2017. PMID: 28217978 Free PMC article.
-
Sex differences in Cardiorenal Syndrome: Insights from CARDIOREN Registry.Curr Heart Fail Rep. 2023 Jun;20(3):157-167. doi: 10.1007/s11897-023-00598-x. Epub 2023 May 24. Curr Heart Fail Rep. 2023. PMID: 37222949 Review.
-
Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.Cardiovasc Diabetol. 2023 Nov 16;22(1):316. doi: 10.1186/s12933-023-02023-y. Cardiovasc Diabetol. 2023. PMID: 37974185 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous